Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial)

BACKGROUND: Transient tachypnea of the newborn (TTN), which results from inadequate absorption of fetal lung fluid, is the most common cause of neonatal respiratory distress. Stimulation of β-adrenergic receptors enhances alveolar fluid absorption. Therefore, the β2-adrenergic receptor agonist salbu...

Descripción completa

Detalles Bibliográficos
Autores principales: Madajczak, Dariusz, Daboval, Thierry, Lauterbach, Ryszard, Łoniewska, Beata, Błaż, Witold, Szczapa, Tomasz, Sadowska-Krawczenko, Iwona, Michalak-Kloc, Marzena, Sławska, Helena, Borszewska-Kornacka, Maria, Bokiniec, Renata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879660/
https://www.ncbi.nlm.nih.gov/pubmed/36714639
http://dx.doi.org/10.3389/fped.2022.1060843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879660/
https://www.ncbi.nlm.nih.gov/pubmed/36714639
http://dx.doi.org/10.3389/fped.2022.1060843

Ejemplares similares